Addex Therapeutics (ADXN) EBIAT: 2022-2025
Historic EBIAT for Addex Therapeutics (ADXN) over the last 3 years, with Jun 2025 value amounting to -$2.2 million.
- Addex Therapeutics' EBIAT fell 115.62% to -$2.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$9,430.7 billion, marking a year-over-year decrease of 208.65%. This contributed to the annual value of $8.0 million for FY2024, which is 168.24% up from last year.
- According to the latest figures from Q2 2025, Addex Therapeutics' EBIAT is -$2.2 million, which was down 35.75% from -$1.6 million recorded in Q1 2025.
- In the past 5 years, Addex Therapeutics' EBIAT ranged from a high of $8,679.9 billion in Q4 2023 and a low of -$9,430.7 billion during Q4 2024.
- Over the past 3 years, Addex Therapeutics' median EBIAT value was -$2.4 million (recorded in 2023), while the average stood at -$75.1 billion.
- Its EBIAT has fluctuated over the past 5 years, first spiked by 40,194,262.97% in 2023, then crashed by 208.65% in 2024.
- Quarterly analysis of 4 years shows Addex Therapeutics' EBIAT stood at -$21.6 million in 2022, then spiked by 40,194,262.97% to $8,679.9 billion in 2023, then tumbled by 208.65% to -$9,430.7 billion in 2024, then plummeted by 115.62% to -$2.2 million in 2025.
- Its EBIAT was -$2.2 million in Q2 2025, compared to -$1.6 million in Q1 2025 and -$9,430.7 billion in Q4 2024.